This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tibet Pharmaceuticals Announces Availability Of Updated Investor Fact Sheet

SHANGRI-LA COUNTY, China, April 18, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, announces the availability of an updated online Investor Fact Sheet.

"As part of our mission to keep investors informed with the latest developments at the company, we are pleased to release our updated fact sheet," said Taylor Guo, Chief Executive Officer at Tibet Pharmaceuticals. "As demonstrated by our recently announced fully-audited financial results, fiscal 2010 was a tremendous year for our company, having grown revenue 41% to $32.4 million and net income 42% to $13.1 million, compared to fiscal 2009.  In light of Tibet Pharmaceuticals' solid results, the traditional Tibetan medicine market represents an extremely fragmented business, with no clear leaders and plenty of room for growth through consolidation. This presents a tremendous opportunity for Tibet Pharmaceuticals and we plan to take advantage of this through potential accretive acquisitions in 2011."

"We look forward to increasing communication with the investor community over the next several weeks and on a more proactive basis going forward," continued Mr. Guo.  "We remain committed to the highest levels of compliance in the US capital markets and we intend to provide updates on our business opportunities and future growth initiatives as we strive to improve our revenues, earnings and, ultimately, create long term value for our shareholders."

The Investor Fact Sheet provides a clear overview of Tibet Pharmaceuticals' business model and growth potential in China's traditional Tibetan medicine market, and is a great resource for both existing shareholders and prospective investors alike.  

The fact sheet is available at:

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 full-time employees and national-wide distributors, the company develops both prescription and over-the-counter ("OTC") traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably the Yunnan Province, where the company's 52,000 sq. ft. fully GMP-certified manufacturing facilities are located.  The access to key raw materials is not generally available outside the province and provides a significant advantage for Tibet Pharmaceuticals.

For more information on Tibet Pharmaceuticals, please visit:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs